Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SGMS2 | Q8NHU3 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23411359 | 1.00 | TSHR (0.37) | TSHRUSP2ALDH1A1NPSR1THRB | |
| SCHEMBL23410934 | 0.94 | HDAC6 (0.39) | TSHRUSP2ALDH1A1NPSR1THRB | |
| SCHEMBL29890887 | 0.94 | HDAC6 (0.39) | TSHRUSP2ALDH1A1NPSR1THRB | |
| SCHEMBL29890426 | 0.86 | NPSR1 (0.36) | TSHRUSP2ALDH1A1NPSR1THRB | |
| SCHEMBL23410722 | 0.86 | NPSR1 (0.36) | TSHRUSP2ALDH1A1NPSR1THRB | |
| SCHEMBL23410883 | 0.85 | LMNA (0.48) | TSHRUSP2ALDH1A1NPSR1THRB | |
| SCHEMBL29890195 | 0.85 | LMNA (0.48) | TSHRUSP2ALDH1A1NPSR1THRB | |
| SCHEMBL23411092 | 0.84 | KDM4E (0.36) | LMNASGMS2KMT2APOLB | |
| SCHEMBL29890496 | 0.84 | KDM4E (0.36) | LMNASGMS2KMT2APOLB | |
| SCHEMBL23410521 | 0.83 | KMT2A (0.38) | TSHRUSP2ALDH1A1NPSR1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661869-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS AND MODULATORS | Bayer Aktiengesellschaft (DE) | 2025-12-17 | — | — | EP | claimed |
| EP-4661870-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-12-17 | — | — | EP | claimed |
| CN-119523983-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-02-28 | — | — | CN | claimed |
| CN-119424429-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-02-14 | — | — | CN | claimed |
| CN-115003665-B | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2024-11-08 | — | — | CN | claimed |
| WO-2024165470-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-15 | — | — | WO | claimed |
| WO-2024165469-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS AND MODULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-15 | — | — | WO | claimed |
| EP-4065574-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | Bayer Aktiengesellschaft (DE) | 2022-10-05 | — | — | EP | claimed |
| CN-115003665-A | Substituted aminoquinolones as immunoactive DGK alpha inhibitors | 拜耳公司 | 2022-09-02 | — | — | CN | claimed |
| EP-4661870-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-12-17 | — | — | EP | disclosed |
| EP-4661906-A1 | COMBINATION OF CCR8 ANTIBODIES WITH DGK INHIBITORS IN THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-12-17 | — | — | EP | disclosed |
| EP-4661869-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS AND MODULATORS | Bayer Aktiengesellschaft (DE) | 2025-12-17 | — | — | EP | disclosed |
| CN-119564686-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119523983-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-115003665-B | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2024-11-08 | — | — | CN | disclosed |
| WO-2024165470-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-15 | — | — | WO | disclosed |
| WO-2024165468-A1 | COMBINATION OF CCR8 ANTIBODIES WITH DGK INHIBITORS IN THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-15 | — | — | WO | disclosed |
| WO-2024165469-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS AND MODULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-15 | — | — | WO | disclosed |
| EP-4065574-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | Bayer Aktiengesellschaft (DE) | 2022-10-05 | — | — | EP | disclosed |
| CN-115003665-A | Substituted aminoquinolones as immunoactive DGK alpha inhibitors | 拜耳公司 | 2022-09-02 | — | — | CN | disclosed |